IN2012DN02730A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02730A
IN2012DN02730A IN2730DEN2012A IN2012DN02730A IN 2012DN02730 A IN2012DN02730 A IN 2012DN02730A IN 2730DEN2012 A IN2730DEN2012 A IN 2730DEN2012A IN 2012DN02730 A IN2012DN02730 A IN 2012DN02730A
Authority
IN
India
Prior art keywords
compounds
antagonists
lpa
medicaments
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Ryan Clark
Brian Andrew Stearns
Jill Melissa Scott
Heather Renee Coate
Lucy Zhao
Thomas Jon Seiders
Deborah Volkots
Jeannie M Arruda
Nicholas Simon Stock
Yen Pham Truong
David Nathan Zalatan
Original Assignee
Amira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43128100&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN02730(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amira Pharmaceuticals Inc filed Critical Amira Pharmaceuticals Inc
Publication of IN2012DN02730A publication Critical patent/IN2012DN02730A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2730DEN2012 2009-10-01 2010-09-29 IN2012DN02730A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24787709P 2009-10-01 2009-10-01
PCT/US2010/050787 WO2011041462A2 (en) 2009-10-01 2010-09-29 Polycyclic compounds as lysophosphatidic acid receptor antagonists

Publications (1)

Publication Number Publication Date
IN2012DN02730A true IN2012DN02730A (enExample) 2015-09-11

Family

ID=43128100

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2702DEN2012 IN2012DN02702A (enExample) 2009-10-01 2010-09-29
IN2730DEN2012 IN2012DN02730A (enExample) 2009-10-01 2010-09-29

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2702DEN2012 IN2012DN02702A (enExample) 2009-10-01 2010-09-29

Country Status (21)

Country Link
US (3) US8664220B2 (enExample)
EP (2) EP2483269A4 (enExample)
JP (2) JP2013506680A (enExample)
KR (1) KR20120097490A (enExample)
CN (2) CN102770415B (enExample)
AR (1) AR078495A1 (enExample)
AU (1) AU2010300594A1 (enExample)
BR (1) BR112012007102A2 (enExample)
CA (1) CA2776779A1 (enExample)
CL (1) CL2012000812A1 (enExample)
EA (1) EA201270467A1 (enExample)
GB (1) GB2474748B (enExample)
IL (1) IL218962A0 (enExample)
IN (2) IN2012DN02702A (enExample)
MX (1) MX2012003723A (enExample)
PE (1) PE20120997A1 (enExample)
PH (1) PH12012500572A1 (enExample)
TN (1) TN2012000126A1 (enExample)
TW (1) TWI415849B (enExample)
UY (1) UY32923A (enExample)
WO (2) WO2011041461A2 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
NZ736048A (en) 2010-06-03 2019-09-27 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
JP5781606B2 (ja) 2010-06-16 2015-09-24 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド インフルエンザ、一般的な感冒および炎症の治療におけるレボセチリジンおよびモンテルカストの使用
US8785442B2 (en) 2011-01-30 2014-07-22 Curegenix, Inc. Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
KR101369584B1 (ko) 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
AU2012258575B2 (en) * 2011-05-25 2017-03-02 Intermune, Inc. Pirfenidone and anti-fibrotic therapy in selected patients
EP2742029B1 (en) * 2011-08-08 2016-10-05 Merck Patent GmbH N-(benzimimdazol-2-yl)-cyclopropane carboxamides as lysophosphatidic acid antagonists
KR20140067048A (ko) 2011-08-15 2014-06-03 인터뮨, 인크. 라이소포스파티드산 수용체 길항제
GB2493914A (en) * 2011-08-19 2013-02-27 Univ Jw Goethe Frankfurt Main Flurbiprofen and related compounds for the treatment of skin diseases
WO2013070879A1 (en) * 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
MX2014006130A (es) 2011-11-22 2015-04-13 Intermune Inc Metodos de diagnostico y tratamiento de la fibrosis pulmonar idiopatica.
US20140329871A1 (en) * 2011-12-04 2014-11-06 Angion Biomedica Corp. Small molecule anti-fibrotic compounds and uses thereof
BR112014030685A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
DK3360869T3 (da) 2012-12-28 2020-10-12 Ube Industries Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.
CN103965664B (zh) * 2013-01-25 2015-07-22 中国石油化工股份有限公司 一种碳黑粒子分散剂及其制备方法和应用
EP2969010B1 (en) 2013-03-13 2017-10-11 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
KR20150135339A (ko) * 2013-03-13 2015-12-02 인플래머토리 리스폰스 리서치, 아이엔씨. 레보세티리진 및 몬테루카스트의 외상성 손상의 치료 용도
WO2014164285A2 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
GB201314926D0 (en) 2013-08-20 2013-10-02 Takeda Pharmaceutical Novel Compounds
JP2017502010A (ja) * 2013-12-20 2017-01-19 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対して多重モードの活性を有するピペリジン誘導体
JP2017078022A (ja) * 2014-02-28 2017-04-27 クミアイ化学工業株式会社 イソキサゾール誘導体及びそれを用いた農園芸用植物病害防除剤
ES2824801T3 (es) 2014-06-27 2021-05-13 Ube Industries Sal de compuesto heterocíclico sustituido con halógeno
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
JP2018503610A (ja) * 2014-12-23 2018-02-08 ファーマサイクリックス エルエルシー Ｂｔｋ阻害剤の組み合わせ及び投与レジメン
US9729562B2 (en) 2015-03-02 2017-08-08 Harris Corporation Cross-layer correlation in secure cognitive network
WO2016197009A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2019041340A1 (en) * 2017-09-04 2019-03-07 Eli Lilly And Company LYSOPHOSPHATIDE ACID RECEPTOR 1 RECEPTOR INHIBITORS (LPAR1)
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US10647705B2 (en) 2017-11-14 2020-05-12 Merck Sharp & Dohme Corp. Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
CN109776351B (zh) * 2017-11-15 2021-11-09 江苏优士化学有限公司 一种重氮乙酸酯连续化合成方法
US11384067B2 (en) 2017-12-19 2022-07-12 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as LPA antagonists
ES2942767T3 (es) * 2017-12-19 2023-06-06 Bristol Myers Squibb Co Isoxazol azoles del ácido ciclohexílico como antagonistas del LPA
EP3728209B1 (en) 2017-12-19 2025-12-24 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
WO2019126103A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azoles as lpa antagonists
US11180488B2 (en) 2017-12-19 2021-11-23 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists
CN112041304B (zh) 2017-12-19 2025-03-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸
NZ766284A (en) 2017-12-19 2023-07-28 Bristol Myers Squibb Co Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3728196B1 (en) 2017-12-19 2023-04-05 Bristol-Myers Squibb Company Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7299892B2 (ja) 2017-12-19 2023-06-28 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
KR20200100713A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
MX2020005323A (es) 2017-12-19 2020-08-13 Bristol Myers Squibb Co Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
CN108379275B (zh) * 2018-05-29 2020-05-22 中国医学科学院阜外医院 溶血磷脂酸、溶血磷脂酸受体3以及溶血磷脂酸受体3激动剂的应用
KR102788997B1 (ko) 2018-09-18 2025-03-28 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
US12209072B2 (en) 2018-09-18 2025-01-28 Bristol-Myers Squibb Company Cyclopentyl acids as LPA antagonists
AU2019393770B2 (en) 2018-12-03 2025-02-20 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
CN114599640A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑羧酸
CN114599641A (zh) 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的环丁基羧酸
JP7431961B2 (ja) 2019-11-15 2024-02-15 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用
EP4085056A1 (en) 2020-01-03 2022-11-09 Berg LLC Polycyclic amides as ube2k modulators for treating cancer
WO2021195360A1 (en) 2020-03-27 2021-09-30 Landos Biopharma, Inc. Plxdc2 ligands
EP4153178A4 (en) 2020-05-19 2024-06-05 Irr, Inc. Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof
CA3185689A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
KR102809527B1 (ko) * 2021-01-22 2025-05-21 서울대학교산학협력단 G 단백질 연결 수용체의 억제제를 이용한 상아질 재생 촉진용 조성물 및 제제
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
AU2022273631B2 (en) 2021-05-11 2025-04-17 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
EP4337654A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物
CN114907282B (zh) * 2022-05-24 2023-08-22 华南理工大学 一种合成4-苯基烯基异噁唑衍生物的方法
WO2024249867A1 (en) * 2023-06-02 2024-12-05 Am Sciences Compounds for treating fibrotic diseases
AU2024317450A1 (en) * 2023-07-28 2026-02-19 Wuhan Createrna Science And Technology Co., Ltd. Compound as lpar1 antagonist, pharmaceutical composition thereof and use thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
ATE236890T1 (de) 1996-12-23 2003-04-15 Bristol Myers Squibb Pharma Co Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer
JP3237608B2 (ja) 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
DE60003025T2 (de) 1999-04-02 2004-03-18 Bristol-Myers Squibb Pharma Co. Arylsulfonyle als faktor xa inhibitoren
DK1258484T3 (da) * 2000-02-18 2009-04-20 Kyowa Hakko Kirin Co Ltd Nye isoxazol- og thiazolforbindelser og anvendelse deraf som lægemidler
AU4456601A (en) * 2000-03-28 2001-10-08 Nippon Soda Co., Ltd. Oxa(thia)zolidine derivative and anti-inflammatory drug
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
WO2002040458A1 (en) 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JPWO2003007991A1 (ja) 2001-07-17 2004-11-04 小野薬品工業株式会社 Ｌｐａ受容体調節剤からなる膵液分泌制御剤
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
JP4569106B2 (ja) 2001-12-25 2010-10-27 味の素株式会社 臓器線維化抑制剤
JP2003261545A (ja) 2001-12-28 2003-09-19 Takeda Chem Ind Ltd 神経栄養因子産生・分泌促進剤
US20050101518A1 (en) * 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050113283A1 (en) 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
KR100704215B1 (ko) * 2002-03-05 2007-04-10 오노 야꾸힝 고교 가부시키가이샤 8-아자프로스타글란딘 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
US20040014662A1 (en) 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
US7285680B2 (en) 2002-05-28 2007-10-23 Ono Pharmaceutical Co., Ltd. β-alanine derivatives and the use thereof
EP1550461A1 (en) * 2002-06-26 2005-07-06 Ono Pharmaceutical Co., Ltd. Remedy for chronic disease
EP2565178A1 (en) 2002-10-03 2013-03-06 Ono Pharmaceutical Co., Ltd. LPA Receptor Antagonists
US20040171037A1 (en) 2002-11-19 2004-09-02 Jing Li Amplified genes involved in cancer
US20040192739A1 (en) 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US20050065194A1 (en) 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US20040167132A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
KR20060025132A (ko) 2003-04-11 2006-03-20 더 유니버시티 오브 테네시 리서치 파운데이션 리소포스파티드산 유사체 및 신생내막 형성의 저해
US7115642B2 (en) * 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
CA2524054C (en) 2003-05-19 2012-04-24 Irm Llc Immunosuppressant compounds and compositions
JP4692281B2 (ja) 2003-08-05 2011-06-01 味の素株式会社 新規アゾール化合物
EP1678096B1 (en) 2003-10-09 2012-01-04 University of Tennessee Research Foundation Lpa receptor agonists and antagonists and methods of use
JP4766384B2 (ja) 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
DE10360369A1 (de) 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
WO2005123671A1 (ja) * 2004-06-22 2005-12-29 Taisho Pharmaceutical Co., Ltd. ピロール誘導体
JP2006096712A (ja) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤
EP1893591A1 (en) 2005-06-08 2008-03-05 Novartis AG POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
MX2008002540A (es) 2005-08-23 2008-03-14 Irm Llc Compuestos inmunosupresores y composiciones.
WO2007096647A2 (en) 2006-02-27 2007-08-30 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
WO2007139946A2 (en) 2006-05-25 2007-12-06 University Of Tennessee Research Foundation Gpcr ligands identified by computational modeling
EP2054424A1 (en) 2006-07-24 2009-05-06 University Of Virginia Patent Foundation Vinyl phosphonate lysophosphatidic acid receptor antagonists
US20080051372A1 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
WO2008024979A2 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
US20100143381A1 (en) 2007-03-12 2010-06-10 Andrew Tager Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
SG190620A1 (en) 2008-05-05 2013-06-28 Sanofi Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
JP4933512B2 (ja) 2008-10-09 2012-05-16 住友化学株式会社 導光板
US8455499B2 (en) 2008-12-11 2013-06-04 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US8592402B2 (en) 2009-08-04 2013-11-26 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
KR20120114371A (ko) * 2010-01-06 2012-10-16 애플 인크. 검색 결과들 사이에서 방향을 맵핑하기 위한 장치, 방법 및 그래픽 사용자 인터페이스

Also Published As

Publication number Publication date
IN2012DN02702A (enExample) 2015-09-04
CN102656168B (zh) 2015-04-01
US8664220B2 (en) 2014-03-04
TW201125862A (en) 2011-08-01
BR112012007102A2 (pt) 2016-04-26
CN102656168A (zh) 2012-09-05
WO2011041462A3 (en) 2011-08-11
GB201016312D0 (en) 2010-11-10
PE20120997A1 (es) 2012-08-01
US20110082164A1 (en) 2011-04-07
TWI415849B (zh) 2013-11-21
JP2013506680A (ja) 2013-02-28
CN102770415B (zh) 2014-09-24
EP2483251A4 (en) 2013-05-01
CN102770415A (zh) 2012-11-07
US8778983B2 (en) 2014-07-15
GB2474748A (en) 2011-04-27
KR20120097490A (ko) 2012-09-04
EP2483269A4 (en) 2013-05-01
JP2013506679A (ja) 2013-02-28
PH12012500572A1 (en) 2012-10-22
US10000456B2 (en) 2018-06-19
EA201270467A1 (ru) 2012-09-28
US20140256744A1 (en) 2014-09-11
UY32923A (es) 2010-11-30
IL218962A0 (en) 2012-07-31
EP2483251A2 (en) 2012-08-08
EP2483269A2 (en) 2012-08-08
EP2483251B1 (en) 2016-10-26
CL2012000812A1 (es) 2012-09-07
WO2011041461A3 (en) 2011-08-25
MX2012003723A (es) 2012-05-08
WO2011041462A2 (en) 2011-04-07
WO2011041461A2 (en) 2011-04-07
TN2012000126A1 (en) 2013-09-19
AU2010300594A1 (en) 2012-05-17
GB2474748B (en) 2011-10-12
CA2776779A1 (en) 2011-04-07
US20130072490A1 (en) 2013-03-21
AR078495A1 (es) 2011-11-09

Similar Documents

Publication Publication Date Title
IN2012DN02735A (enExample)
IN2012DN02702A (enExample)
IN2012DN00754A (enExample)
PH12013501136A1 (en) Lysophosphatidic acid receptor antagonists and uses thereof
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2010077882A3 (en) Antagonists of lysophosphatidic acid receptors
PH12020550450A1 (en) Certain chemical entities, compositions and methods
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
PH12013500481A1 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
WO2010068775A3 (en) Alkyne antagonists of lysophosphatidic acid receptors
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
IN2012DN02471A (enExample)
TN2010000463A1 (en) Compositions and methods for preparing and using same